SANTINI, DANIELE
 Distribuzione geografica
Continente #
NA - Nord America 23
AS - Asia 4
EU - Europa 1
Totale 28
Nazione #
US - Stati Uniti d'America 23
HK - Hong Kong 3
IT - Italia 1
LB - Libano 1
Totale 28
Città #
Buffalo 2
Chicago 2
Henderson 2
New York 2
Ashburn 1
Beirut 1
Castelfidardo 1
Herndon 1
Los Angeles 1
Portland 1
Reston 1
Rochester 1
San Francisco 1
Scottsdale 1
Secaucus 1
Totale 19
Nome #
Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance?, file e18b8791-e3cc-d302-e053-1705fe0a27c8 7
Corrigendum: Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? [Ann Oncol, 23, 9, (2012) (2313-2318)] doi: 10.1093/annonc/mdr623, file e18b8791-e3ca-d302-e053-1705fe0a27c8 5
Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: A literature-based meta-analysis, file e18b8791-ee07-d302-e053-1705fe0a27c8 4
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: A retrospective analysis, file e18b8791-e5a9-d302-e053-1705fe0a27c8 3
A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients, file e18b8791-ecc9-d302-e053-1705fe0a27c8 3
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients, file e18b8791-ee01-d302-e053-1705fe0a27c8 3
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis, file e18b8791-ef03-d302-e053-1705fe0a27c8 3
Totale 28
Categoria #
all - tutte 316
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 316


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/202327 7 0 3 8 0 1 2 6 0 0 0 0
2023/20241 0 0 0 1 0 0 0 0 0 0 0 0
Totale 28